Navigation Links
ARCA biopharma Appoints James Carr as Vice President of Marketing

BROOMFIELD, Colo., Aug. 1 /PRNewswire/ -- ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that it has appointed James Carr, PharmD, as vice president of marketing. In this newly created position, Mr. Carr will define and execute marketing programs to support the company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator in late-stage development for heart failure.

"Jim brings senior pharmaceutical industry experience and a deep knowledge of the heart failure market, which will be of significant value to ARCA as the company prepares to commercialize the first personalized cardiovascular medicine," said Richard B. Brewer, president and chief executive officer of ARCA. "We are pleased to be able to attract talented professionals to help us accelerate the company's growth and success, and welcome Jim to the ARCA team."

Mr. Carr joins ARCA from Anesiva, Inc., where he served as vice president of marketing for pain management products since 2004. In this role, he was responsible for leading the development and launch teams for Zingo(TM), a rapid acting topical anesthetic. Prior to Anesiva, Mr. Carr was with GlaxoSmithKline (GSK) for eight years, where he led the launch for the post-myocardial infarction indication for Coreg(R) (carvedilol), a leading treatment for heart failure. During his tenure at GSK, Carr held management positions in professional relations, managed care marketing, medical education, advisory boards, publications, and lifecycle management.

Prior to joining the pharmaceutical industry, Mr. Carr was a researcher at the University at Buffalo School of Pharmacy. He earned a Doctor of Pharmacy degree from the University of Minnesota and conducted post-graduate work in the area of polymorphic drug metabolism of beta-blockers, also at the University of Minnesota.

About ARCA biopharma

ARCA biopharma, Inc. is a privately held company focused on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product, Gencaro(TM) (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that predict individual patient response to Gencaro. The company plans to file a New Drug Application with the U.S. Food and Drug Administration during the summer of 2008 for approval of Gencaro for the treatment of heart failure. The companion genetic test for Gencaro is in development by ARCA's partner, Laboratory Corporation of America. If approved, Gencaro could become the first genetically personalized cardiovascular therapy. For more information please visit

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the environment are paramount. Insertion points for in-line sensors can represent a weak ... the InTrac 781/784 series of retractable sensor housings , which are designed ...
(Date:11/24/2015)... Capricor Therapeutics, Inc. (NASDAQ: ... development and commercialization of first-in-class therapeutics, today announced that ... scheduled to present at the 2015 Piper Jaffray Healthcare ... at The Lotte New York Palace Hotel in ... . --> . ...
(Date:11/24/2015)... ... , ... Whitehouse Laboratories is pleased to announce that it has completed construction ... dedicated to basic USP 61, USP 62 and USP 51 testing specific to raw ... and micro testing performed by one supplier. Management has formally announced that ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
Breaking Biology News(10 mins):